Extended-Spectrum β-lactamase-Producing Enterobacteriaceae in an Italian Intensive Care Unit: Clinical and Therapeutical Remarks

REFERENCES

• Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28 (2): 302–7.
   PubMed Web of Science ®Google Scholar
• Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14 (4): 933–51.
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of beta-lactamases. Phil Trans R Soc Lond Biol Sci 1980; 289 (1036): 321–31.
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classifi-cation scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39 (6): 1211–33.
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35 (9): 1697–704.
   PubMed Web of Science ®Google Scholar
• Peñla C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spec-trum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35 (1): 9-16.
   Google Scholar
• National Nosocomial Infection Surveillance (NNIS) System Report. Data summary from January 1990 - May 1999, issued June 1999. Am J Infect Contr 1999; 27: 520–32.
   Google Scholar
• Stobberingh EE, Arends J, Hoogkamp-Korstanje JA et al. Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals. Infection 1999; 27 (6): 348–54.
   Google Scholar
• Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemina-tion of Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol 1998; 47 (3): 201–9.
   PubMed Web of Science ®Google Scholar
• yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoni-ae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184 (1): 53–6.
   PubMed Web of Science ®Google Scholar
• Ho PL, Tsang DN, Que TL, Ho M, Yuen KY. Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among Escherichia coli and Klebsiella species in Hong Kong. APMIS 2000; 108 (3): 237–40.
   PubMed Web of Science ®Google Scholar
• Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occur-rence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30 (3): 454–60.
   PubMed Web of Science ®Google Scholar
• Essack SY. Laboratory detection of extended-spectrum beta-lactamases (ESBLs). The need for a reliable, reproducible method. Diagn Microbiol Infect Dis 2000; 37 (4): 293–5.
   PubMed Web of Science ®Google Scholar
• Hollander R, Ebke M, Barck H, von Pritzbuer E. Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase by patients in a neurologi-cal early rehabilitation unit: management of an outbreak. J Hosp Infect 2001; 48 (3): 207–13.
   PubMed Web of Science ®Google Scholar
• Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME. Characterization of an outbreak due to extended-spec-trum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000; 31 (6): 1368–72.
   PubMed Web of Science ®Google Scholar
• Perla C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneu-mo n iae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42: 53–58.
   PubMed Web of Science ®Google Scholar
• Gruteke P, Goessens W, Van Gils J et al. Patterns of resistance associated with integrons, the extended-spectrum beta-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak. J Clin Microbiol 2003; 41 (3): 1161-6.
   Google Scholar
• Yu WL, Jones RN, Hollis RJ et al. Molecular epidemi-ology of extended-spectrum beta-lactamase-producing, fluoro-quinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40 (12): 4666-9.
   Google Scholar
• Quale JM, Landman D, Bradford PA et al. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002; 35 (7): 834-41.
   Google Scholar
• smith pg, Tomfohrde KM, Rhoden DL, Balows A. API system: a multitube micromethod for identification of Enterobacteriaceae. Appl Microbiol 1972; 24 (3): 449-52.
   Google Scholar
• National Committee of Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement NCCLS, 2002.
   Google Scholar
• Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867–78.
   PubMedGoogle Scholar
• National Committee of Clinical Laboratory Standards. Fact sheet: laboratory detection of extended-spectrum beta-lac-tamases (ESBL). See: http://www.cdc.gov/ncidod/hip/Lab/FactSheet/esbl.htm.
   Google Scholar
• Emori TG, Edwards JR, Culver DH et al. Accuracy of reporting nosocomial infections in intensive-care-unit patients to the National Nosocomial Infections Surveillance System: a pilot study. Infect Contr Hosp Epidemiol 1998; 19 (5): 308–16.
   Google Scholar
• Du B, Long Y, Liu H et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumo-niae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28 (12): 1718-23.
   Google Scholar
• Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183–9.
   Google Scholar
• De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 2000; 45: 537–9.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae: an Italian survey. Int J Antimicrob Agents 2002; 19: 213–7.
   PubMed Web of Science ®Google Scholar
• Mutnick AH, Turner PJ, Jones RN. Emerging antimi-crobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. J Chemother 2002; 14 (3): 253–8.
   Google Scholar